Loading…
Sex Hormone Receptor Repertoire in Breast Cancer
Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions us...
Saved in:
Published in: | International Journal of Breast Cancer 2013-01, Vol.2013 (2013), p.50-63 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3 |
---|---|
cites | cdi_FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3 |
container_end_page | 63 |
container_issue | 2013 |
container_start_page | 50 |
container_title | International Journal of Breast Cancer |
container_volume | 2013 |
creator | Higa, Gerald M. Fell, Ryan G. |
description | Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer. |
doi_str_mv | 10.1155/2013/284036 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e688a76f271245858af3adaf90674919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A373578717</galeid><airiti_id>P20151207002_201312_201708020006_201708020006_50_63</airiti_id><doaj_id>oai_doaj_org_article_e688a76f271245858af3adaf90674919</doaj_id><sourcerecordid>A373578717</sourcerecordid><originalsourceid>FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3</originalsourceid><addsrcrecordid>eNqFkttrFDEUhwdRbKl98llZEESUbXO_vAh1UVspKF6ewzFzsptldrJNZr3892Z36tIFwcxDMjnf-chMfk3zmJIzSqU8Z4Tyc2YE4epec8yIJVNOjb2_X2ty1JyWsiR1SMq50g-bIyY4E8aK44Z8wV-Ty5RXqcfJZ_S4HlKuizXmIcWMk9hP3mSEMkxm0HvMj5oHAbqCp7fzSfPt3duvs8vp9cf3V7OL6ylIa4dpsEEQT6linHpgsmXcKxnAMgg0UPCtUQEFcquV9chQES_RsBYkaqOAnzRXo7dNsHTrHFeQf7sE0e02Up47yEP0HTpUxoBWgWnKhDTSQODQQrBEaWGpra7Xo2u9-b7C1mM_ZOgOpIeVPi7cPP1w3AgpiKyCF7eCnG42WAa3isVj10GPaVMcrRSllGtT0WcjOod6tNiHVI1-i7sLrrnURlNdqbN_UPVpcRV9vYsQ6_5Bw_M7DQuEbliU1G2GmPpyCL4aQZ9TKRnD_jMpcdvIuG1k3BiZSj-9-2f27N-AVODlCCxi38LP-B_bkxHGimCAPSwUYWJb_zDWIeY4RLdMm9zXELlP1SIpI5oQtjPS3aSJIazmVh2-SOIU538Aaubh3A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540111378</pqid></control><display><type>article</type><title>Sex Hormone Receptor Repertoire in Breast Cancer</title><source>Wiley Open Access</source><source>PubMed Central</source><creator>Higa, Gerald M. ; Fell, Ryan G.</creator><contributor>Ejlertsen, Bent</contributor><creatorcontrib>Higa, Gerald M. ; Fell, Ryan G. ; Ejlertsen, Bent</creatorcontrib><description>Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.</description><identifier>ISSN: 2090-3170</identifier><identifier>ISSN: 2090-3189</identifier><identifier>EISSN: 2090-3189</identifier><identifier>DOI: 10.1155/2013/284036</identifier><identifier>PMID: 24324894</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Analysis ; Breast cancer ; Hormones, Sex ; Physiological aspects ; Review</subject><ispartof>International Journal of Breast Cancer, 2013-01, Vol.2013 (2013), p.50-63</ispartof><rights>Copyright © 2013 Gerald M. Higa and Ryan G. Fell.</rights><rights>COPYRIGHT 2013 John Wiley & Sons, Inc.</rights><rights>Copyright © 2013 G. M. Higa and R. G. Fell. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3</citedby><cites>FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3</cites><orcidid>0000-0001-7919-1468</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845405/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845405/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24324894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ejlertsen, Bent</contributor><creatorcontrib>Higa, Gerald M.</creatorcontrib><creatorcontrib>Fell, Ryan G.</creatorcontrib><title>Sex Hormone Receptor Repertoire in Breast Cancer</title><title>International Journal of Breast Cancer</title><addtitle>Int J Breast Cancer</addtitle><description>Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.</description><subject>Analysis</subject><subject>Breast cancer</subject><subject>Hormones, Sex</subject><subject>Physiological aspects</subject><subject>Review</subject><issn>2090-3170</issn><issn>2090-3189</issn><issn>2090-3189</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkttrFDEUhwdRbKl98llZEESUbXO_vAh1UVspKF6ewzFzsptldrJNZr3892Z36tIFwcxDMjnf-chMfk3zmJIzSqU8Z4Tyc2YE4epec8yIJVNOjb2_X2ty1JyWsiR1SMq50g-bIyY4E8aK44Z8wV-Ty5RXqcfJZ_S4HlKuizXmIcWMk9hP3mSEMkxm0HvMj5oHAbqCp7fzSfPt3duvs8vp9cf3V7OL6ylIa4dpsEEQT6linHpgsmXcKxnAMgg0UPCtUQEFcquV9chQES_RsBYkaqOAnzRXo7dNsHTrHFeQf7sE0e02Up47yEP0HTpUxoBWgWnKhDTSQODQQrBEaWGpra7Xo2u9-b7C1mM_ZOgOpIeVPi7cPP1w3AgpiKyCF7eCnG42WAa3isVj10GPaVMcrRSllGtT0WcjOod6tNiHVI1-i7sLrrnURlNdqbN_UPVpcRV9vYsQ6_5Bw_M7DQuEbliU1G2GmPpyCL4aQZ9TKRnD_jMpcdvIuG1k3BiZSj-9-2f27N-AVODlCCxi38LP-B_bkxHGimCAPSwUYWJb_zDWIeY4RLdMm9zXELlP1SIpI5oQtjPS3aSJIazmVh2-SOIU538Aaubh3A</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Higa, Gerald M.</creator><creator>Fell, Ryan G.</creator><general>Hindawi Limiteds</general><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AFFIF</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7919-1468</orcidid></search><sort><creationdate>20130101</creationdate><title>Sex Hormone Receptor Repertoire in Breast Cancer</title><author>Higa, Gerald M. ; Fell, Ryan G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Analysis</topic><topic>Breast cancer</topic><topic>Hormones, Sex</topic><topic>Physiological aspects</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Higa, Gerald M.</creatorcontrib><creatorcontrib>Fell, Ryan G.</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>قاعدة دراسات المرأة - e-Marefa Women Studies</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International Journal of Breast Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Higa, Gerald M.</au><au>Fell, Ryan G.</au><au>Ejlertsen, Bent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sex Hormone Receptor Repertoire in Breast Cancer</atitle><jtitle>International Journal of Breast Cancer</jtitle><addtitle>Int J Breast Cancer</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>2013</volume><issue>2013</issue><spage>50</spage><epage>63</epage><pages>50-63</pages><issn>2090-3170</issn><issn>2090-3189</issn><eissn>2090-3189</eissn><abstract>Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>24324894</pmid><doi>10.1155/2013/284036</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-7919-1468</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2090-3170 |
ispartof | International Journal of Breast Cancer, 2013-01, Vol.2013 (2013), p.50-63 |
issn | 2090-3170 2090-3189 2090-3189 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_e688a76f271245858af3adaf90674919 |
source | Wiley Open Access; PubMed Central |
subjects | Analysis Breast cancer Hormones, Sex Physiological aspects Review |
title | Sex Hormone Receptor Repertoire in Breast Cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A40%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sex%20Hormone%20Receptor%20Repertoire%20in%20Breast%20Cancer&rft.jtitle=International%20Journal%20of%20Breast%20Cancer&rft.au=Higa,%20Gerald%20M.&rft.date=2013-01-01&rft.volume=2013&rft.issue=2013&rft.spage=50&rft.epage=63&rft.pages=50-63&rft.issn=2090-3170&rft.eissn=2090-3189&rft_id=info:doi/10.1155/2013/284036&rft_dat=%3Cgale_doaj_%3EA373578717%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1540111378&rft_id=info:pmid/24324894&rft_galeid=A373578717&rft_airiti_id=P20151207002_201312_201708020006_201708020006_50_63&rfr_iscdi=true |